{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-110797","form_type":"8-K","ticker":"ELUT","cik":"0001708527","company_name":"ELUTIA INC.","filed_at":"2022-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.786480+00:00","generated_at":"2026-06-23T01:40:52.654595+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aziyo Biologics appoints David Colpman to board; regains Nasdaq audit committee compliance","bullets":["David Colpman appointed to Board of Directors and audit committee effective Oct. 20, 2022; board size increased to six.","Colpman brings over 25 years of healthcare business development experience, including senior roles at Shire, Novo Nordisk, Glaxo Wellcome.","Appointment resolves Nasdaq noncompliance with Rule 5605(c)(2) (audit committee independence deficiency) created by Dr. Mills' role change.","Colpman currently serves as advisor to HighCape Capital, affiliate of HighCape Partners, a controlling stockholder of Aziyo.","CEO Dr. Randy Mills highlights Colpman's transaction experience as valuable for strategic partnerships and near-term priorities."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-110797","json":"https://secwatch.observer/filing/0001104659-22-110797.json","markdown":"https://secwatch.observer/filing/0001104659-22-110797.md","text":"https://secwatch.observer/filing/0001104659-22-110797.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708527/000110465922110797/0001104659-22-110797-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708527/000110465922110797/tm2228791d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T01:40:52.654595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5cd759f8da","claim":"David Colpman was appointed as Director at ELUTIA INC..","evidence_excerpt":"the Company) increased the size of the Board from a total of five to six directors and appointed David Colpman to the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708527/000110465922110797/0001104659-22-110797-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}